Finally, several TF inhibitors are currently in clinical trials (e.g., SY-1365, a CDK7 inhibitor altering gene expression, including Runt-related transcription factor 1 (RUNX1) expression in advanced solid tumors) or in use (e.g., the estrogen receptor inhibitor Tamoxifen) to treat cancers [189]. The gene discussed is RUNX1; the disease is cancer.